{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:15:07Z","timestamp":1767665707544},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.remn.2018.02.007","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T18:55:02Z","timestamp":1523645702000},"page":"330-337","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radio-223 en el tratamiento de met\u00e1stasis \u00f3seas en pacientes con c\u00e1ncer de pr\u00f3stata resistente a la castraci\u00f3n. Revisi\u00f3n de la literatura y procedimiento"],"prefix":"10.1016","volume":"37","author":[{"given":"J.","family":"Orcajo-Rincon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.P.","family":"Caresia-Ar\u00f3ztegui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"del Puig C\u00f3zar-Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Garc\u00eda-Garz\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"de Arcocha-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.C.","family":"Delgado-Bolton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Garc\u00eda-Velloso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Alvarez-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Garc\u00eda-Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remn.2018.02.007_bib0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics","volume":"2014","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.remn.2018.02.007_bib0205","doi-asserted-by":"crossref","unstructured":"C\u00f3zar JM, Mi\u00f1ana B, G\u00f3mez-Veiga F, Rodr\u00edguez-Antol\u00edn A, Villavicencio H, 25 Urology Units, Asociaci\u00f3n Espa\u00f1ola de Urolog\u00eda, et al. Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010. BJU Int. 2012(11 Pt B):E701-706.","DOI":"10.1111\/j.1464-410X.2012.11504.x"},{"key":"10.1016\/j.remn.2018.02.007_bib0210","first-page":"322","article-title":"Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours","volume":"16","author":"Dur\u00e1n","year":"2014","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"issue":"8 Suppl","key":"10.1016\/j.remn.2018.02.007_bib0215","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.remn.2018.02.007_bib0220","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"2","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.remn.2018.02.007_bib0225","first-page":"777","article-title":"[Consensus on castration-resistant prostate cancer management in Spain]","volume":"9","author":"Alcaraz","year":"2017","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.remn.2018.02.007_bib0230","unstructured":"NCCN Guidelines on Prostate Cancer versi\u00f3n 2. 2017 [consultado 15 Ene 2018]. Disponible en: https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician gls\/pdf\/prostate.pdf"},{"key":"10.1016\/j.remn.2018.02.007_bib0235","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"3","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.remn.2018.02.007_bib0240","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer","volume":"13","author":"Smith","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.remn.2018.02.007_bib0245","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of relapsing metastatic, and castration-resistant prostate cancer","volume":"4","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.remn.2018.02.007_bib0250","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2013.08.008","article-title":"Castration-resistant prostate cancer: from new pathophysiology to new treatment","volume":"2","author":"Sridhar","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.remn.2018.02.007_bib0255","article-title":"Radium-223 in the therapeutic sequence of metastatic castration-resistant prostate cancer","author":"Unda-Urzaiz","year":"2017","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.remn.2018.02.007_bib0260","first-page":"317","article-title":"The cost of treating skeletal-related events in patients with prostate cancer","volume":"5","author":"Lage","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.remn.2018.02.007_bib0265","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","article-title":"First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases","volume":"12","author":"Nilsson","year":"2005","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.remn.2018.02.007_bib0270","unstructured":"Xofigo INN Radium 223 Choride, Bayer Pharma AG. Summary of Product Characteristics [consultado 1 Ene 2017]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002653\/WC500156172.pdf"},{"key":"10.1016\/j.remn.2018.02.007_bib0275","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.semnuclmed.2014.07.006","article-title":"Radionuclide therapy for osseous metastases in prostate cancer","volume":"1","author":"Abi-Ghanem","year":"2015","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.remn.2018.02.007_bib0280","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"12","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.remn.2018.02.007_bib0285","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(16)30173-5","article-title":"Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial","volume":"9","author":"Saad","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.remn.2018.02.007_bib0290","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/COC.0000000000000181","article-title":"Hematologic toxicity of concurrent administration of radium-223 and next-generation antiandrogen therapies","volume":"4","author":"Dan","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.remn.2018.02.007_bib0295","unstructured":"Radium-223 dichloride and abiraterone acetate compared to placebo and abiraterone acetate for men with cancer of the prostate when medical or surgical castration does not work and when the cancer has spread to the bone, has not been treated with chemotherapy and is causing no or only mild symptoms - Tabular View - ClinicalTrials.gov [consultado 12 Ene 2018]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02043678"},{"issue":"5s","key":"10.1016\/j.remn.2018.02.007_bib0300","article-title":"Effects of radium-223dichloride with docetaxel versus docetaxel on prostate-specific antigen and bone alkaline phosphatase in patients with castration-resistant prostate cancer and bone metastases A phase 1\/2a clinical trial","volume":"33","author":"Morris","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2 Supp 1","key":"10.1016\/j.remn.2018.02.007_bib0305","first-page":"70","article-title":"Practical guide to the use of radium 223 dichloride","author":"Den","year":"2014","journal-title":"Can J Urol"},{"key":"10.1016\/j.remn.2018.02.007_bib0310","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/1060028014565444","article-title":"Radium-223 dichloride: A novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases","volume":"4","author":"McGann","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.remn.2018.02.007_bib0315","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00259-017-3756-7","article-title":"Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer","volume":"10","author":"Du","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remn.2018.02.007_bib0320","unstructured":"Instrucci\u00f3n IS-05, del Consejo de Seguridad Nuclear. Publicado en el BOE n.\u00b0 86 de 10 de abril de 2003 [consultado 18 Ene 2018]. Disponible en: https:\/\/www.boe.es\/buscar\/doc.php?id=BOE-A-2003-7520"},{"key":"10.1016\/j.remn.2018.02.007_bib0325","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/MNM.0b013e328353bb6e","article-title":"Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases","volume":"7","author":"Hindorf","year":"2012","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.remn.2018.02.007_bib0330","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2013.50.3201","article-title":"Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy","volume":"31","author":"Halabi","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.remn.2018.02.007_bib0335","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-11-0815","article-title":"Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response","volume":"14","author":"Ryan","year":"2011","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.remn.2018.02.007_bib0395","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","article-title":"Visceral disease in castration-resistant prostate cancer","volume":"65","author":"Pezaro","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.remn.2018.02.007_bib0340","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11307-009-0239-7","article-title":"The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT","volume":"1","author":"Beheshti","year":"2010","journal-title":"Mol Imaging Biol MIB Off Publ Acad Mol Imaging"},{"key":"10.1016\/j.remn.2018.02.007_bib0345","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1158\/1078-0432.CCR-03-0735","article-title":"Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer","volume":"8","author":"Michaelson","year":"2004","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.remn.2018.02.007_bib0350","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advanced prostate cancer: Recommendations of the St. Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"26","author":"Gillessen","year":"2016","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.remn.2018.02.007_bib0355","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2214\/AJR.05.0225","article-title":"Flare response in 18F-fluoride ion PET bone scanning","volume":"6","author":"Wade","year":"2006","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.remn.2018.02.007_bib0360","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1078-0432.CCR-09-2514","article-title":"Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer","volume":"1","author":"Armstrong","year":"2010","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.remn.2018.02.007_bib0365","first-page":"374","article-title":"Diagnosis of bone metastasis: recent comparative studies of imaging modalities","volume":"4","author":"Talbot","year":"2011","journal-title":"Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Of"},{"key":"10.1016\/j.remn.2018.02.007_bib0375","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7150\/jca.1.80","article-title":"Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST","volume":"1","author":"Costelloe","year":"2010","journal-title":"J Cancer"},{"key":"10.1016\/j.remn.2018.02.007_bib0380","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"2","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.remn.2018.02.007_bib0385","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s00259-016-3439-9","article-title":"Prospective evaluation of [11C]Choline PET\/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer","volume":"12","author":"Schwarzenb\u00f6ck","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remn.2018.02.007_bib0390","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00259-017-3900-4","article-title":"EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer","volume":"45","author":"Poeppel","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X17302743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X17302743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T16:16:58Z","timestamp":1571156218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253654X17302743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S2253654X17302743"],"URL":"https:\/\/doi.org\/10.1016\/j.remn.2018.02.007","relation":{},"ISSN":["2253-654X"],"issn-type":[{"type":"print","value":"2253-654X"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radio-223 en el tratamiento de met\u00e1stasis \u00f3seas en pacientes con c\u00e1ncer de pr\u00f3stata resistente a la castraci\u00f3n. Revisi\u00f3n de la literatura y procedimiento","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2018.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}